172 related articles for article (PubMed ID: 34833153)
1. Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Zhang Y; La B; Liang B; Gu Y
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833153
[TBL] [Abstract][Full Text] [Related]
2. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
3. Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Zhang Y; Wang J; Hu T; Wang H; Long M; Liang B
Life (Basel); 2022 Nov; 12(12):. PubMed ID: 36556355
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
5. Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Yang W; Li S; Yang Q
Medicine (Baltimore); 2019 May; 98(20):e15731. PubMed ID: 31096532
[TBL] [Abstract][Full Text] [Related]
6. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
7. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Ge Y; Zhang H; Weygant N; Yao J
Front Pharmacol; 2021; 12():640099. PubMed ID: 34447305
[No Abstract] [Full Text] [Related]
8. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Guo X; Li W; Hu J; Zhu EC; Su Q
Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
11. Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.
Su Q; Zhang X; Shen X; Hou Y; Sun Z; Gao ZH
J Cancer; 2018; 9(9):1614-1622. PubMed ID: 29760800
[No Abstract] [Full Text] [Related]
12. Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis.
Liu Y; Zhang X; Wang G; Cui X
Front Oncol; 2021; 11():693655. PubMed ID: 34195094
[TBL] [Abstract][Full Text] [Related]
13. Toxicities associated with immune checkpoint inhibitors: a systematic study.
Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
[TBL] [Abstract][Full Text] [Related]
14. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis.
Zhao P; Zhao T; Yu L; Ma W; Liu W; Zhang C
Front Oncol; 2024; 14():1381250. PubMed ID: 38756658
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.
Wang Y; Kong D; Wang C; Chen J; Li J; Liu Z; Li X; Wang Z; Yao G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820967454. PubMed ID: 33084525
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
17. Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Li J; Gu J
J Clin Pharmacol; 2019 Jan; 59(1):45-54. PubMed ID: 30088662
[TBL] [Abstract][Full Text] [Related]
18. Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis.
Zou D; Wang X; Sun Y; Wang X; Lu C; Wang A; Wang X; Yang Y
Front Oncol; 2023; 13():1258287. PubMed ID: 37841432
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhuansun Y; Huang F; Du Y; Lin L; Chen R; Li J
J Thorac Dis; 2017 Mar; 9(3):655-665. PubMed ID: 28449473
[TBL] [Abstract][Full Text] [Related]
20. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.
Wang BC; Cao RB; Li PD; Fu C
Cancer Med; 2019 Oct; 8(13):5969-5978. PubMed ID: 31436392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]